Does the media favor UTHR or REGN?

In the previous week, United Therapeutics had 6 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.21 beat United Therapeutics' score of 0.83 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 15 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or ALNY?

In the previous week, United Therapeutics had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 0.83 beat Alnylam Pharmaceuticals' score of 0.28 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor UTHR or BIIB?

In the previous week, United Therapeutics had 5 more articles in the media than Biogen. MarketBeat recorded 22 mentions for United Therapeutics and 17 mentions for Biogen. United Therapeutics' average media sentiment score of 0.83 beat Biogen's score of 0.71 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 10 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INCY or UTHR?

In the previous week, United Therapeutics had 9 more articles in the media than Incyte. MarketBeat recorded 22 mentions for United Therapeutics and 13 mentions for Incyte. United Therapeutics' average media sentiment score of 0.83 beat Incyte's score of 0.78 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NBIX or UTHR?

In the previous week, United Therapeutics had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 10 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.83 beat Neurocrine Biosciences' score of 0.47 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

United Therapeutics (UTHR) Competitors

$555.91 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$555.00 -0.91 (-0.16%)

As of 07/2/2026 07:57 PM Eastern

Compare

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

Should you buy United Therapeutics stock or one of its competitors? MarketBeat compares United Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with United Therapeutics include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

In the previous week, United Therapeutics had 6 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.21 beat United Therapeutics' score of 0.83 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	15 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.09	20.52
Regeneron Pharmaceuticals	$14.34B	4.82	$4.50B	$41.04	15.94

United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

United Therapeutics has a net margin of 40.62% compared to Regeneron Pharmaceuticals' net margin of 29.65%. United Therapeutics' return on equity of 19.24% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

United Therapeutics presently has a consensus price target of $619.42, indicating a potential upside of 11.42%. Regeneron Pharmaceuticals has a consensus price target of $792.65, indicating a potential upside of 21.15%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.73

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Alnylam Pharmaceuticals?

United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, United Therapeutics had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 0.83 beat Alnylam Pharmaceuticals' score of 0.28 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

United Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

United Therapeutics has higher earnings, but lower revenue than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.09	20.52
Alnylam Pharmaceuticals	$3.71B	11.24	$313.75M	$3.66	85.46

United Therapeutics currently has a consensus target price of $619.42, suggesting a potential upside of 11.42%. Alnylam Pharmaceuticals has a consensus target price of $461.39, suggesting a potential upside of 47.51%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Summary

United Therapeutics beats Alnylam Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Biogen?

United Therapeutics (NASDAQ:UTHR) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, United Therapeutics had 5 more articles in the media than Biogen. MarketBeat recorded 22 mentions for United Therapeutics and 17 mentions for Biogen. United Therapeutics' average media sentiment score of 0.83 beat Biogen's score of 0.71 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	10 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics presently has a consensus price target of $619.42, indicating a potential upside of 11.42%. Biogen has a consensus price target of $217.41, indicating a potential upside of 0.60%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Biogen	2 Sell rating(s)	12 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.52

United Therapeutics has a net margin of 40.62% compared to Biogen's net margin of 13.81%. United Therapeutics' return on equity of 19.24% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Biogen	13.81%	12.83%	8.01%

United Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

United Therapeutics has higher earnings, but lower revenue than Biogen. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.09	20.52
Biogen	$9.89B	3.23	$1.29B	$9.32	23.19

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

United Therapeutics beats Biogen on 13 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Incyte has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

United Therapeutics has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.54	$1.29B	$7.08	16.51
United Therapeutics	$3.18B	7.41	$1.33B	$27.09	20.52

Incyte presently has a consensus target price of $107.85, indicating a potential downside of 7.71%. United Therapeutics has a consensus target price of $619.42, indicating a potential upside of 11.42%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe United Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, United Therapeutics had 9 more articles in the media than Incyte. MarketBeat recorded 22 mentions for United Therapeutics and 13 mentions for Incyte. United Therapeutics' average media sentiment score of 0.83 beat Incyte's score of 0.78 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Incyte on 10 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Neurocrine Biosciences currently has a consensus target price of $187.52, indicating a potential upside of 7.61%. United Therapeutics has a consensus target price of $619.42, indicating a potential upside of 11.42%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, United Therapeutics had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 10 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.83 beat Neurocrine Biosciences' score of 0.47 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	6.13	$478.60M	$6.49	26.85
United Therapeutics	$3.18B	7.41	$1.33B	$27.09	20.52

Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Neurocrine Biosciences on 12 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.60B	$3.10B	$7.19B	$12.47B
Dividend Yield	N/A	2.05%	2.67%	6.51%
P/E Ratio	20.52	20.06	27.99	24.69
Price / Sales	7.41	357.08	535.28	98.64
Price / Cash	16.85	57.49	49.26	57.09
Price / Book	3.37	4.32	10.96	6.46
Net Income	$1.33B	$64.45M	$3.57B	$337.01M
7 Day Performance	2.44%	2.97%	2.12%	1.69%
1 Month Performance	1.50%	3.39%	2.80%	0.67%
1 Year Performance	88.72%	29.07%	33.40%	23.93%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	4.499 of 5 stars	$555.91 flat	$619.42 +11.4%	+88.7%	$23.60B	$3.18B	20.52	1,400	Trending News Insider Trade
REGN Regeneron Pharmaceuticals	4.8529 of 5 stars	$631.81 -0.2%	$792.65 +25.5%	+20.0%	$66.91B	$14.34B	15.39	15,410	Positive News Analyst Downgrade Gap Down
ALNY Alnylam Pharmaceuticals	4.2301 of 5 stars	$293.52 +0.7%	$461.39 +57.2%	-5.8%	$38.90B	$3.71B	80.20	2,770	Analyst Revision Gap Down
BIIB Biogen	3.4592 of 5 stars	$216.63 +0.3%	$217.41 +0.4%	+63.0%	$31.89B	$9.89B	23.24	7,500
INCY Incyte	3.9782 of 5 stars	$114.66 +0.8%	$107.85 -5.9%	+70.7%	$22.73B	$5.14B	16.19	2,844	Options Volume Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does United Therapeutics compare to Biogen?

Summary

How does United Therapeutics compare to Incyte?

Summary

How does United Therapeutics compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Does the media favor UTHR or REGN?

Which has higher earnings and valuation, UTHR or REGN?

Which has more volatility and risk, UTHR or REGN?

Do institutionals and insiders hold more shares of UTHR or REGN?

Is UTHR or REGN more profitable?

Do analysts rate UTHR or REGN?

Summary

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Does the media favor UTHR or ALNY?

Which has more volatility & risk, UTHR or ALNY?

Do institutionals and insiders have more ownership in UTHR or ALNY?

Which has stronger earnings & valuation, UTHR or ALNY?

Do analysts prefer UTHR or ALNY?

Is UTHR or ALNY more profitable?

Summary

How does United Therapeutics compare to Biogen?

Does the media favor UTHR or BIIB?

Do analysts recommend UTHR or BIIB?

Is UTHR or BIIB more profitable?

Which has more risk and volatility, UTHR or BIIB?

Which has higher valuation and earnings, UTHR or BIIB?

Do institutionals and insiders hold more shares of UTHR or BIIB?

Summary

How does United Therapeutics compare to Incyte?

Which has more risk & volatility, INCY or UTHR?

Which has stronger valuation & earnings, INCY or UTHR?

Do analysts prefer INCY or UTHR?

Does the media refer more to INCY or UTHR?

Do insiders & institutionals believe in INCY or UTHR?

Is INCY or UTHR more profitable?

Summary

How does United Therapeutics compare to Neurocrine Biosciences?

Do analysts recommend NBIX or UTHR?

Do institutionals and insiders have more ownership in NBIX or UTHR?

Does the media refer more to NBIX or UTHR?

Which has stronger valuation & earnings, NBIX or UTHR?

Which has more volatility and risk, NBIX or UTHR?

Is NBIX or UTHR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools